Quantum BioPharma files IND for Lucid‑MS
What happened
Quantum BioPharma announced it submitted an Investigational New Drug application to the FDA for Lucid‑MS, a Phase 2 trial targeting multiple sclerosis and neuroprotection. An IND filing starts formal regulatory interactions and triggers the need for prespecified safety monitoring plans unique to demyelinating disease trials. Tracking this IND matters for competitor intelligence and for anticipating neuro‑specific adverse event signal frameworks. (x.com)
Why it matters
Quantum BioPharma dated the regulatory filing April 1, 2026 and lists the program internally as Lucid‑21‑302; the company says it anticipates starting patient dosing in the second quarter of 2026 if the U.S. regulator clears the file. (feeds.issuerdirect.com) An initial human study in healthy volunteers found once‑daily oral doses of 150 mg and 300 mg were generally well tolerated with no serious adverse events reported. (neurologylive.com) Quantum completed required 180‑day chronic toxicology studies to support its clinical dossier. (clinicaltrialvanguard.com) Quantum has named Dr. Salvatore Napoli as principal investigator for the planned mid‑stage study. (markets.financialcontent.com) The company has a binding letter with a contract research organization — a vendor that runs and manages clinical trials — Allucent for study execution, and previously contracted a third‑party manufacturer to produce the oral drug product. (pharmasource.global, multiplesclerosisnewstoday.com) Technically, Lucid‑MS is reported as a small‑molecule inhibitor of an enzyme called PAD2 (protein arginine deiminase 2); PAD2 is an enzyme that converts arginine residues in proteins into citrulline, a chemical change linked to instability of myelin (the nerve‑insulating sheath) in multiple sclerosis, and the program is described by the sponsor as non‑immunomodulatory (meaning it does not primarily suppress the immune system). (neurologylive.com, mdpi.com) Phase 1 pharmacokinetics showed dose‑proportional exposure with peak concentrations rising roughly from 1.5–2.1 µg/mL at 150 mg to 2.8–3.3 µg/mL at 300 mg, and the trial reported 38 treatment‑emergent adverse events across 12 of 40 participants with no severe or serious events attributed to the drug; those human data and the chronic toxicology reports form the core of the clinical and safety package included in the regulatory submission. (neurologylive.com, clinicaltrialvanguard.com) For surveillance design and signal detection, expect regulators and imaging experts to press for standardized MRI acquisition and central reads (centralized image review by an independent core) to detect new or enlarging lesions and to separate inflammatory relapses from chronic progression—international MRI consortia publish consensus acquisition and reporting standards that regulators reference. (thelancet.com) Separately, U.S. IND safety reporting rules require expedited sponsor reports for suspected, serious and unexpected adverse reactions — within seven calendar days for unexpected fatal or life‑threatening events and within 15 calendar days for other serious unexpected events — under 21 CFR 312.32, and sponsors must remain prepared for rapid follow‑up information requests. (ecfr.gov, fda.gov) Preclinical and translational literature introduce concrete on‑target safety questions that should be prespecified as adjudicated events: genetic or pharmacologic PAD2 loss has been reported to impair oligodendrocyte differentiation and reduce numbers of myelinated axons in mouse models (a signal for potential motor/cognitive sequelae), while separate studies show PAD2 inhibition can alter innate immune functions such as neutrophil extracellular trap formation in sepsis models — these findings support adding targeted neurological function batteries and specific immune biomarkers to the safety plan and defining event adjudication criteria up front. (biorxiv.org, insight.jci.org) The regulatory consequence of adverse safety signals can be swift: the agency can place an application or ongoing study on clinical hold if it finds subjects would face an unreasonable and significant risk or if the IND lacks sufficient information to assess risk; sponsors should therefore expect detailed agency review of toxicology, investigator qualifications and the investigator brochure during the regulatory review window. (ecfr.gov)
Key numbers
- Quantum BioPharma announced it submitted an Investigational New Drug application to the FDA for Lucid‑MS, a Phase 2 trial targeting multiple sclerosis and neuroprotection.
- (x.com) Quantum BioPharma dated the regulatory filing April 1, 2026 and lists the program internally as Lucid‑21‑302; the company says it anticipates starting patient dosing in the second quarter of 2026 if the U.S.
- (feeds.issuerdirect.com) An initial human study in healthy volunteers found once‑daily oral doses of 150 mg and 300 mg were generally well tolerated with no serious adverse events reported.
- (neurologylive.com) Quantum completed required 180‑day chronic toxicology studies to support its clinical dossier.
What happens next
- An IND filing starts formal regulatory interactions and triggers the need for prespecified safety monitoring plans unique to demyelinating disease trials.
Quick answers
What happened in Quantum BioPharma files IND for Lucid‑MS?
Quantum BioPharma announced it submitted an Investigational New Drug application to the FDA for Lucid‑MS, a Phase 2 trial targeting multiple sclerosis and neuroprotection. An IND filing starts formal regulatory interactions and triggers the need for prespecified safety monitoring plans unique to demyelinating disease trials. Tracking this IND matters for competitor intelligence and for anticipating neuro‑specific adverse event signal frameworks. (x.com)
Why does Quantum BioPharma files IND for Lucid‑MS matter?
Quantum BioPharma dated the regulatory filing April 1, 2026 and lists the program internally as Lucid‑21‑302; the company says it anticipates starting patient dosing in the second quarter of 2026 if the U.S. regulator clears the file. (feeds.issuerdirect.com) An initial human study in healthy volunteers found once‑daily oral doses of 150 mg and 300 mg were generally well tolerated with no serious adverse events reported. (neurologylive.com) Quantum completed required 180‑day chronic toxicology studies to support its clinical dossier. (clinicaltrialvanguard.com) Quantum has named Dr. Salvatore Napoli as principal investigator for the planned mid‑stage study. (markets.financialcontent.com) The company has a binding letter with a contract research organization — a vendor that runs and manages clinical trials — Allucent for study execution, and previously contracted a third‑party manufacturer to produce the oral drug product. (pharmasource.global, multiplesclerosisnewstoday.com) Technically, Lucid‑MS is reported as a small‑molecule inhibitor of an enzyme called PAD2 (protein arginine deiminase 2); PAD2 is an enzyme that converts arginine residues in proteins into citrulline, a chemical change linked to instability of myelin (the nerve‑insulating sheath) in multiple sclerosis, and the program is described by the sponsor as non‑immunomodulatory (meaning it does not primarily suppress the immune system). (neurologylive.com, mdpi.com) Phase 1 pharmacokinetics showed dose‑proportional exposure with peak concentrations rising roughly from 1.5–2.1 µg/mL at 150 mg to 2.8–3.3 µg/mL at 300 mg, and the trial reported 38 treatment‑emergent adverse events across 12 of 40 participants with no severe or serious events attributed to the drug; those human data and the chronic toxicology reports form the core of the clinical and safety package included in the regulatory submission. (neurologylive.com, clinicaltrialvanguard.com) For surveillance design and signal detection, expect regulators and imaging experts to press for standardized MRI acquisition and central reads (centralized image review by an independent core) to detect new or enlarging lesions and to separate inflammatory relapses from chronic progression—international MRI consortia publish consensus acquisition and reporting standards that regulators reference. (thelancet.com) Separately, U.S. IND safety reporting rules require expedited sponsor reports for suspected, serious and unexpected adverse reactions — within seven calendar days for unexpected fatal or life‑threatening events and within 15 calendar days for other serious unexpected events — under 21 CFR 312.32, and sponsors must remain prepared for rapid follow‑up information requests. (ecfr.gov, fda.gov) Preclinical and translational literature introduce concrete on‑target safety questions that should be prespecified as adjudicated events: genetic or pharmacologic PAD2 loss has been reported to impair oligodendrocyte differentiation and reduce numbers of myelinated axons in mouse models (a signal for potential motor/cognitive sequelae), while separate studies show PAD2 inhibition can alter innate immune functions such as neutrophil extracellular trap formation in sepsis models — these findings support adding targeted neurological function batteries and specific immune biomarkers to the safety plan and defining event adjudication criteria up front. (biorxiv.org, insight.jci.org) The regulatory consequence of adverse safety signals can be swift: the agency can place an application or ongoing study on clinical hold if it finds subjects would face an unreasonable and significant risk or if the IND lacks sufficient information to assess risk; sponsors should therefore expect detailed agency review of toxicology, investigator qualifications and the investigator brochure during the regulatory review window. (ecfr.gov)
